e-learning
resources
Virtual 2020
Pre-Congress Content
Microbiology and antimicrobial strategies in cystic fibrosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Clinical surveys with nebulised hypertonic saline (HS) in CF children
. Bernek (Starnberg, Germany), M. Ollmann-Selinger (Gräfelfing, Germany), R. Ledermüller (Starnberg, Germany)
Source:
Virtual Congress 2020 – Microbiology and antimicrobial strategies in cystic fibrosis
Session:
Microbiology and antimicrobial strategies in cystic fibrosis
Session type:
E-poster session
Number:
696
Disease area:
Paediatric lung diseases, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
. Bernek (Starnberg, Germany), M. Ollmann-Selinger (Gräfelfing, Germany), R. Ledermüller (Starnberg, Germany). Clinical surveys with nebulised hypertonic saline (HS) in CF children. 696
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Cystic fibrosis and intestinal organoids
Clinics of Cystic Fibrosis Patients with Unusual Bacteria Isolated fromRespiratory Cultures
Novel therapeutics for cystic fibrosis
Related content which might interest you:
Audit of once daily nebulised hypertonic 6% saline (HTS) in adult bronchiectasis
Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management
Year: 2010
A single blind study to compare nebulised hypertonic saline (7%) and normal saline (0.9%) as an adjunct to physiotherapy airway clearance in patients with bronchiectasis
Source: Eur Respir J 2005; 26: Suppl. 49, 304s
Year: 2005
Comparison of magnesium sulfate to normal saline as a vehicle for nebulized salbutamol in children with acute asthma; a clinical trial
Source: Annual Congress 2008 - Treatment and outcome of childhood asthma: new perspectives
Year: 2008
Safety and efficacy of 7% hypertonic saline in patients with bronchiectasis
Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine
Year: 2013
Nebulized hypertonic saline in the treatment of viral bronchiolitis in infants
Source: Annual Congress 2007 - Bronchiolitis - viruses, treatment and outcome
Year: 2007
Inhaled hypertonic saline + hyaluronic acid (HSHA) and HS alone in patients with Cystic Fibrosis (CF): a 2 years retrospective analysis in Treviso’s CF Unit.
Source: International Congress 2017 – Cystic fibrosis: clinical issues
Year: 2017
Nebulised hypertonic saline in the treatment of viral bronchiolitis in infants
Source: ISSN=ISSN 1810-6838, ISBN=, page=160
Year: 2007
Inhalation therapy with hypertonic saline (3%) – A treatment option for airway disease in children?
Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care
Year: 2015
Effect of inhaled hypertonic saline solution to treat infants hospitalized with viral bronchiolitis
Source: Annual Congress 2011 - Viral respiratory infections in children: causes and consequences
Year: 2011
Effectiveness of nebulised hypertonic saline on the respiratory management of children and young people with neuromuscular disease
Source: International Congress 2019 – Innovations in care for chronic respiratory conditions
Year: 2019
Efficacy of hypertonic saline solution in infant with acute bronchiolitis
Source: Annual Congress 2007 - Bronchiolitis - viruses, treatment and outcome
Year: 2007
7% hypertonic saline and hyaluronic acid and in the treatment of infants mild-moderate bronchiolitis
Source: Annual Congress 2011 - Viral respiratory infections in children: causes and consequences
Year: 2011
Is nebulized saline a placebo in COPD?
Source: Eur Respir J 2001; 18: Suppl. 33, 184s
Year: 2001
Success rate of sputum induction in the Leicester paediatric severe asthma clinic using nebulised hypertonic saline: A 2-year review
Source: Annual Congress 2010 - Paediatric asthma treatment and monitoring
Year: 2010
RCT Abstract - The effect of inhaled hypertonic saline on lung structure in preschool children with cystic fibrosis
Source: Virtual Congress 2021 – Cystic fibrosis in children: various aspects
Year: 2021
Oxygen saturation decrease after both isotonic and hypertonic saline inhalation in COPD patients
Source: Eur Respir J 2005; 26: Suppl. 49, 698s
Year: 2005
Nebulized saline treatment in patients with concomitant asthma and bronchiectasis
Source: Virtual Congress 2021 – Bronchiectasis and pleural infection
Year: 2021
Nebulized 3% hypertonic saline in the treatment of acute bronchiolitis in infants
Source: Annual Congress 2013 –Difficult and rare respiratory infections
Year: 2013
Inhaled fraction and granulometry of hypertonic saline solution Aerosol for the ambulatory management of newborn babies with viral bronchiolitis: size matters.
Source: International Congress 2018 – Paediatric respiratory infections: mechanistic insights and clinical outcomes
Year: 2018
Hyaluronic acid improves tolerability to 7% hypertonic saline solution in bronchiectasis patients
Source: International Congress 2018 – Pulmonary drug delivery: inhaler use, devices and technologies
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept